Molecular Therapeutic Targets for Glioma Angiogenesis
Figure 12
Clinical course of a case with recurrent malignant glioma with bevacizumab and CPT11 treatment. After 3 cycles enhanced tumor and perifocal edema is markedly diminished (Bev 2 m). However, after 6 cycles T2 high intense tumors regrow with minimal enhancement (Bev 4 m).
